45 days later, BioCryst abandons another program, citing stiff competition

[cafead]

via Last month, BioCryst trimmed down its pipeline to two drugs in complement-mediated diseases: BCX9930 and BCX10013. Fast-forward 45 days and BCX9930 is headed to the garbage can, too.

article source